Skip to content

Citius Oncology, Inc. CTOR Deferred Tax Liabilities, Gross

Deferred Tax Liabilities, Gross at other companies

Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilities.

The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s deferred tax liabilities, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s deferred tax liabilities, gross?
Citius Oncology, Inc. (CTOR) reported deferred tax liabilities, gross of $2.78M in Q3 2025.
What is the long-term trend for Citius Oncology, Inc.'s deferred tax liabilities, gross?
Over 2 years (2023 to 2025), Citius Oncology, Inc.'s deferred tax liabilities, gross has grown at a 55.5% compound annual growth rate (CAGR), from $1.15M to $2.78M.